Obesity. Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
Conditions
Interventions
Intervention 1: Intervention group: The group receiving the time-restricted feeding diet. The time-restricted feeding diet will be considered as a 16:8 diet, and this is how people have a 16-hour hung
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
19 Years to 49 Years
Inclusion criteria
Inclusion criteria: Obese women with a body mass index of 30-35 kg/m2 Women in the age range of 19-49 years Women who have not gone through menopause
Exclusion criteria
Exclusion criteria: History of any disease such as hypertension, cardiovascular, liver, kidney diseases, cancers, mental and psychological diseases, and in general any type of disease that affects a person's diet. Drug abuse such as smoking or alcoholism according to the person's own statements. Taking any medication or dietary supplement that affects appetite such as antidepressants-steroids or contraceptives. Pregnancy Breastfeeding Having a special and unusual diet plan within the last 3 months. Having weight loss plans within the last 3 months. Having a job that requires working the night shift.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMAL-1 gene expression. Timepoint: This variable will be measured at baseline and before the start of the study and at the end of the study (week 12). Method of measurement: quantitative polymerase chain reaction method.;MiRNA-let-7f gene expression. Timepoint: This variable will be measured at baseline and before the start of the study and at the end of the study (week 12). Method of measurement: The quantitative polymerase chain reaction method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Weight will be measured at baseline, before the start of the intervention, and at the end of the study, i.e., week 12. Method of measurement: scale.;Height. Timepoint: Body mass index will be measured at baseline, before the start of the intervention, and at the end of the study, i.e., week 12. Method of measurement: height gauge.;Body composition. Timepoint: Body composition index will be measured at baseline, before the start of the intervention, and at the end of the study, i.e. week 12. Method of measurement: Bioelectrical Impedance Analysis device.;Blood sugar. Timepoint: Blood sugar will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;Insulin. Timepoint: Insulin will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;Total cholesterol. Timepoint: Total cholesterol will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;Triglyceride. Timepoint: Triglyceride will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;High-density cholesterol. Timepoint: High density-cholesterol will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;Low-density cholesterol. Timepoint: Low density-cholesterol will be measured at the beginning of the study, before the start of the treatment, and at the end of the study, i.e. week 12. Method of measurement: laboratory kit.;Sleep quality. Timepoint: Sleep quality will be assessed at the beginning, before the intervention begins, and at the end, at week 12. Method of measurement: t | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahram Pourghassem Gargari
Tabriz University of Medical Sciences
Outcome results
None listed